Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2016 Dec 7;16(1):505.
doi: 10.1186/s12906-016-1486-1.

Protocol of a prospective study for the combination treatment of Shu-Gan-jian-Pi decoction and steroid standard therapy in autoimmune hepatitis patients

Xiao-Ling Chi  1 , Huan-Ming Xiao  2 , Yu-Bao Xie  2 , Gao-Shu Cai  2 , Jun-Min Jiang  2 , Guang-Jun Tian  2 , Mei-Jie Shi  2 , Shu-Duo Wu  2 , Peng-Tao Zhao  2 , Hui-Jun Chen  2
Affiliations
Controlled Clinical Trial

Protocol of a prospective study for the combination treatment of Shu-Gan-jian-Pi decoction and steroid standard therapy in autoimmune hepatitis patients

Xiao-Ling Chi et al. BMC Complement Altern Med. .

Abstract

Background: Prednisone plus azathioprine is considered the mainstay of therapy in the current recommendations for autoimmune hepatitis (AIH). However, it does not provide good benefits for AIH patients because of its serious side effects. Therefore, more and more AIH patients prefer to seek for traditional Chinese medicine (TCM) to manage their symptoms and reduce the side effects of steroids in China. Shu-Gan-Jian-Pi Decoction is a popular used Chinese herbal formula in Guangdong province of China, which has demonstrated the effect of improving efficacy and reducing side effects of corticosteroids in AIH patients. The aim of this study is to evaluate the effects of Shu-Gan-Jian-Pi Decoction combined with steroid in AIH patients. So, this study aims to explore whether the combination treatment of Shu-Gan-Jian-Pi Decoction and steroid standard therapy could improve the clinical management of AIH.

Methods: A prospective non-randomized study on AIH will be conducted between October 2015 and June 2017 in Guangdong Provincial hospital of Chinese medicine. Eligible AIH patients will be classified as the case group (n = 66) and the control group (n = 66) based on the interventions. Patients taking Shu-Gan-Jian-Pi Decoction combined with prednisone and azathioprine will be in the case group and those taking prednisone and azathioprine will be in the control group. The whole study will last 48 weeks, including a 24-week observation period and a 24-week follow-up period. The primary outcome was complete response to therapy, defined as complete biochemical remission at the patient's last visit of observation period and the absence of predefined steroid-specific side effects throughout treatment.

Discussion: This trial will evaluate the efficacy and safety of Shu-Gan-Jian-Pi Decoction combined with prednisone and azathioprine on AIH patients. The achievement of this trial will provide evidence-based data for Shu-Gan-Jian-Pi Decoction, which could provide good benefits for AIH patients.

Trial registration: Chinese Clinical Trial Registry: ChiCTR-OOC-15006155 . Registration date: 28 March 2015.

Keywords: Autoimmune Hepatitis; Shu-Gan-Jian-Pi Decoction; Side effects; Steroid.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of the current trial. PRED: Prednisone; AZA: azathioprine; SGJPD: Shu-Gan-Jian-Pi Decoction
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66. doi: 10.1056/NEJMra050408. - DOI - PubMed
    1. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2010;139(1):58–72. doi: 10.1053/j.gastro.2010.04.053. - DOI - PubMed
    1. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68(2):253–256. doi: 10.1097/00007890-199907270-00016. - DOI - PubMed
    1. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, Everhart J, Detre KM. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28(3):638–645. doi: 10.1002/hep.510280306. - DOI - PubMed
    1. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62. doi: 10.1002/hep.20732. - DOI - PubMed

Publication types

MeSH terms